John A. Radford

John A. Radford

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Journal: Leukemia & lymphoma

Published: February 25, 2026

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation.

Journal: Blood advances

Published: August 05, 2025

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Journal: Blood advances

Published: August 05, 2025

An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.

An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.

Journal: NEJM evidence

Published: June 19, 2025

Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000.

Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 11, 2025

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Journal: Blood advances

Published: December 10, 2024

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.

Journal: Future oncology (London, England)

Published: November 12, 2024

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Journal: Blood advances

Published: October 21, 2024

Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England.

Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England.

Journal: EJHaem

Published: June 07, 2024

Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.

Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 13, 2024

Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.

Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 26, 2023

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.

Journal: Circulation

Published: September 25, 2023

Showing 1-12 of 133

Last Updated: 09/26/2026